Gyre Therapeutics reports FY2024 revenue $105.8M, issues FY2025 guidance $118-128M; Phase 3 data due Q2 2025

GYRE THERAPEUTICS, INC.

FY2024 revenue $105.8M (down 6.8% YoY); net income $17.9M vs loss $85.5M in 2023 on absence of IPR&D charge.
Non-GAAP adjusted net income $16.9M (down from $25.4M); cash $51.2M at year-end.
FY2025 revenue guidance $118-128M (11-21% growth) driven by planned launches of nintedanib and avatrombopag in China.
Pivotal Phase 3 trial of F351 in CHB-associated liver fibrosis topline data expected Q2 2025; U.S. Phase 2 in MASH planned.
Appointed Ping Zhang as lead independent director; Songjiang Ma appointed Chairman of Gyre Pharmaceuticals board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.